معرفی
Dr. Mary Scott is a Research Fellow at the Paul O'Gorman Leukaemia Research Centre within the Wolfson Wohl Cancer Research Centre at the University of Glasgow, focusing on chronic myeloid leukemia (CML) stem cell biology and therapeutic resistance mechanisms.
Her research centers on:
- Metabolic vulnerabilities in leukemic stem cells (arginine dependency, pyruvate anaplerosis)
- Epigenetic reprogramming and EZH2 inhibition strategies
- p53-mediated self-renewal pathways in residual CML disease
- Microenvironment interactions in the bone marrow niche
Recent publications reveal a strong trend toward targeting persistent leukemic stem cells through dual metabolic-epigenetic approaches, with increasing emphasis on mitochondrial metabolism and transcriptional reprogramming as therapeutic avenues.
Dr. Scott's research is supported by active grants:
- 2024-2025: Identification of biomarkers predictive of TKI response in CML (Tenovus Scotland)
- 2023-2026: Functional analysis of leukemia stem cell subtypes in CML (Leukaemia UK)
- 2014-2017: H3K27 methylation modulation for eradicating TKI-persistent CML stem cells (Blood Cancer UK)
She operates within the Paul O'Gorman Leukaemia Research Centre team, utilizing advanced molecular profiling techniques to investigate therapy-resistant CML populations and develop novel eradication strategies.
